ATE489481T1 - Verfahren zur risikobeurteilung, überlebensvorhersage und behandlung von herzversagen und anderen leiden auf der grundlage von polymorphismen adrenerger rezeptoren - Google Patents
Verfahren zur risikobeurteilung, überlebensvorhersage und behandlung von herzversagen und anderen leiden auf der grundlage von polymorphismen adrenerger rezeptorenInfo
- Publication number
- ATE489481T1 ATE489481T1 AT04816181T AT04816181T ATE489481T1 AT E489481 T1 ATE489481 T1 AT E489481T1 AT 04816181 T AT04816181 T AT 04816181T AT 04816181 T AT04816181 T AT 04816181T AT E489481 T1 ATE489481 T1 AT E489481T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- polymorphisms
- beta
- adrenergic receptor
- treatment
- Prior art date
Links
- 102000054765 polymorphisms of proteins Human genes 0.000 title abstract 5
- 206010019280 Heart failures Diseases 0.000 title abstract 3
- 108060003345 Adrenergic Receptor Proteins 0.000 title abstract 2
- 102000017910 Adrenergic receptor Human genes 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000004083 survival effect Effects 0.000 title abstract 2
- 238000012502 risk assessment Methods 0.000 title 1
- 102000005962 receptors Human genes 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 239000002876 beta blocker Substances 0.000 abstract 2
- 229940097320 beta blocking agent Drugs 0.000 abstract 2
- 241000699660 Mus musculus Species 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229960004195 carvedilol Drugs 0.000 abstract 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 229960002237 metoprolol Drugs 0.000 abstract 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50283703P | 2003-09-12 | 2003-09-12 | |
| PCT/US2004/029838 WO2005025409A2 (en) | 2003-09-12 | 2004-09-13 | Methods for risk assessment, survival prediction and treatment of heart failure and other conditions based on adrenergic receptor polymorphisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE489481T1 true ATE489481T1 (de) | 2010-12-15 |
Family
ID=34312422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04816181T ATE489481T1 (de) | 2003-09-12 | 2004-09-13 | Verfahren zur risikobeurteilung, überlebensvorhersage und behandlung von herzversagen und anderen leiden auf der grundlage von polymorphismen adrenerger rezeptoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7449292B2 (de) |
| EP (1) | EP1670954B1 (de) |
| AT (1) | ATE489481T1 (de) |
| AU (1) | AU2004272102A1 (de) |
| CA (1) | CA2538222A1 (de) |
| DE (1) | DE602004030271D1 (de) |
| WO (1) | WO2005025409A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4510630B2 (ja) * | 2002-09-09 | 2010-07-28 | ユニバーシティ オブ シンシナティ | 個体における心血管疾患を評価する方法 |
| EP1838723A4 (de) * | 2004-06-29 | 2008-10-08 | Univ Cincinnati | Polymorphismen und haplotypen des adrenergen alpha-2c-rezeptorgens |
| CA2581086C (en) * | 2004-09-14 | 2023-11-07 | The Regents Of The University Of Colorado, A Body Corporate | Method for treatment with bucindolol based on genetic targeting |
| US7949557B2 (en) | 2005-02-07 | 2011-05-24 | Recyclebank, Llc | Method and system for improving recycling through the use of financial incentives |
| US20090024479A1 (en) * | 2005-02-07 | 2009-01-22 | Recyclebank Llc | Community-based recycling system and methods thereof |
| US10445756B2 (en) * | 2005-02-07 | 2019-10-15 | Recyclebank Llc | System and method for managing an incentive-based recycling program |
| US8602298B2 (en) * | 2005-02-07 | 2013-12-10 | Recyclebank, Llc | Recycling system and method thereof |
| US10354474B2 (en) * | 2005-02-07 | 2019-07-16 | Recyclebank Llc | Incentive-based waste reduction system and method thereof |
| US10410231B2 (en) * | 2005-02-07 | 2019-09-10 | Recyclebank Llc | Method of implementing an incentive-based recycling system |
| US20080269346A1 (en) * | 2005-02-17 | 2008-10-30 | University Of Florida Research Foundation, Inc. | B-Blocker Pharmacogenetics in Heart Failure |
| US7999541B2 (en) * | 2005-05-16 | 2011-08-16 | Rapiscan Security Products, Inc. | System and method for improving the analysis of polymorphic chemical substance forms and concentrations using NQR |
| US20100121700A1 (en) * | 2006-02-02 | 2010-05-13 | David Wigder | System and method for incentive-based resource conservation |
| WO2009018209A1 (en) | 2007-07-27 | 2009-02-05 | The Regents Of The University Of Colorado, A Body Corporate | ENDOTHELIN SINGLE NUCLEOTIDE POLYMORPHISMS AND METHODS OF PREDICTING β-ADRENERGIC RECEPTOR TARGETING AGENT EFFICACY |
| US20090092964A1 (en) * | 2007-09-11 | 2009-04-09 | The University Of Cincinnati | Methods for Individualizing Cardiovascular Disease Treatment Protocols Based on Beta-1 Adrenergic Receptor Haplotype |
| US20100185506A1 (en) * | 2008-07-18 | 2010-07-22 | Wm Greenops, Llc | Systems and methods used in the operation of a recycling enterprise |
| US8799064B2 (en) * | 2009-03-20 | 2014-08-05 | Recyclebank, Llc | System for cross-integration of consumer loyalty programs and methods thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US113725A (en) * | 1871-04-18 | Improvement | ||
| US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5202231A (en) * | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| ATE92538T1 (de) | 1988-01-21 | 1993-08-15 | Genentech Inc | Verstaerkung und nachweis von nukleinsaeuresequenzen. |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5002867A (en) * | 1988-04-25 | 1991-03-26 | Macevicz Stephen C | Nucleic acid sequence determination by multiple mixed oligonucleotide probes |
| AU3694689A (en) | 1988-04-28 | 1989-11-24 | Mark H. Skolnick | Amplified sequence polymorphisms (asps) |
| US5130238A (en) * | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| ATE138106T1 (de) | 1988-07-20 | 1996-06-15 | David Segev | Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen |
| IE66572B1 (en) | 1989-02-13 | 1996-01-24 | Geneco Pty Ltd | Detection of a nucleic acid sequence or a change therein |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5302509A (en) * | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US5169766A (en) * | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
| US6180338B1 (en) | 1992-08-04 | 2001-01-30 | Beckman Coulter, Inc. | Method, reagent and kit for the detection and amplification of nucleic acid sequences |
| IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
| WO1995021271A1 (en) * | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US6498009B1 (en) * | 1997-10-10 | 2002-12-24 | University Of Cincinnati | β-adrenergic receptor polymorphisms |
| DE19938390A1 (de) * | 1999-08-05 | 2001-03-08 | Max Delbrueck Centrum | Neue Sequenzvarianten des menschlichen ßl-Adrenozeptorgens und ihre Verwendung |
| WO2001079561A2 (en) | 2000-04-17 | 2001-10-25 | Liggett Stephen B | Alpha-2 adrenergic receptor polymorphisms |
| US6365618B1 (en) * | 2000-12-13 | 2002-04-02 | Conrad M. Swartz | Administration of carvedilol to mitigate tardive movement disorders, psychosis, mania, and depression |
| WO2002071070A2 (en) * | 2001-02-13 | 2002-09-12 | University Of Florida | β-ADRENOCEPTOR GENETIC POLYMORPHISMS AND OBESITY |
| AU2002358293A1 (en) * | 2001-12-27 | 2003-07-24 | Myriad Genetics, Inc | Drug response marker in beta-1 adrenergic receptor gene |
-
2004
- 2004-09-13 US US10/941,063 patent/US7449292B2/en not_active Expired - Fee Related
- 2004-09-13 AU AU2004272102A patent/AU2004272102A1/en not_active Abandoned
- 2004-09-13 DE DE602004030271T patent/DE602004030271D1/de not_active Expired - Lifetime
- 2004-09-13 CA CA002538222A patent/CA2538222A1/en not_active Abandoned
- 2004-09-13 WO PCT/US2004/029838 patent/WO2005025409A2/en not_active Ceased
- 2004-09-13 AT AT04816181T patent/ATE489481T1/de not_active IP Right Cessation
- 2004-09-13 EP EP04816181A patent/EP1670954B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2538222A1 (en) | 2005-03-24 |
| EP1670954A2 (de) | 2006-06-21 |
| WO2005025409A3 (en) | 2005-12-08 |
| DE602004030271D1 (de) | 2011-01-05 |
| US20050112632A1 (en) | 2005-05-26 |
| US7449292B2 (en) | 2008-11-11 |
| EP1670954A4 (de) | 2006-11-08 |
| EP1670954B1 (de) | 2010-11-24 |
| AU2004272102A1 (en) | 2005-03-24 |
| WO2005025409A2 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE489481T1 (de) | Verfahren zur risikobeurteilung, überlebensvorhersage und behandlung von herzversagen und anderen leiden auf der grundlage von polymorphismen adrenerger rezeptoren | |
| Splawski et al. | Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations | |
| Okamura et al. | Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder | |
| Schmieder et al. | Effect of the angiotensin II type 2-receptor gene (+ 1675 G/A) on left ventricular structure in humans | |
| Swapna et al. | Risk conferred by FokI polymorphism of vitamin D receptor (VDR) gene for essential hypertension | |
| Chung et al. | Determinants of optogenetic cortical spreading depolarizations | |
| Baudin | Polymorphism in angiotensin II receptor genes and hypertension | |
| Nollen et al. | What is new in the Marfan syndrome? | |
| Urzi et al. | Pilot study on genetic associations with age-related sarcopenia | |
| EP1556405A4 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
| Takeda et al. | Congenital contractural arachnodactyly complicated with aortic dilatation and dissection: case report and review of literature | |
| Kelsey et al. | Alpha‐adrenergic receptor gene polymorphisms and cardiovascular reactivity to stress in B lack adolescents and young adults | |
| Thakkinstian et al. | Causal relationship between body mass index and fetuin‐A level in the asian population: a bidirectional mendelian randomization study | |
| Altomare et al. | The allele (A)-110 in the promoter region of the HSP70-1 gene is unfavorable to longevity in women | |
| Arikan et al. | Positive association of macrophage migration inhibitory factor gene‐173G/C polymorphism with biliary atresia | |
| Gardier et al. | A1166C polymorphism of angiotensin II type 1 receptor, blood pressure and arterial stiffness in hypertension | |
| Mehrotra et al. | Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India | |
| Jung et al. | Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin receptor stimulation | |
| Broos et al. | Is PPARα intron 7 G/C polymorphism associated with muscle strength characteristics in nonathletic young men? | |
| Armaroli et al. | Paternal germline mosaicism in collagen VI related myopathies | |
| PATInO-GARCiA et al. | Analysis of the human tumour necrosis factor-alpha (TNFα) gene promoter polymorphisms in children with bone cancer | |
| Rojano-Mejía et al. | Relation of the estrogen receptor and vitamin D receptor polymorphisms with bone mineral density in postmenopausal Mexican-mestizo women | |
| Kolomeichuk et al. | MTNR1A and MTNR1B gene variants of the melatonin receptor and arterial stiffness in persons without arterial hypertension | |
| Butler et al. | Growth hormone receptor (GHR) gene polymorphism and Prader–Willi syndrome | |
| Yang et al. | Association between heat-shock protein 70 gene polymorphisms and DNA damage in peripheral blood lymphocytes among coke-oven workers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |